This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

ARBs in chronic heart failure with reduced ejection fraction in people with chronic kidney disease (CKD)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Treating chronic heart failure with reduced ejection fraction in people with chronic kidney disease

If eGFR 30-60 ml/min/1.73m2

  • if eGFR > 45 ml/min/1,73m2 and < 60 ml/min/1,73m2
    • there is no indication to change doses or titration of suggested therapies indicated for chronic heart failure
      • first line treatments
        • ACEI (or ARB)
        • beta blocker
        • mineralocorticoid receptor antagonist
      • specialist initiated treatments
        • ivabradine
        • sacubutril valsartan
        • digoxin
        • hydralazine and nitrate combination

  • if the person's eGFR is 45 ml/min/1.73m2 or below, consider lower doses and/or slower titration of dose of ACE inhibitors or ARBs, mineralocorticoid receptor antagonists and digoxin

  • if eGFR below 30ml/min/1.73m2
    • specialist heart failure MDT should consider liaising with a renal physician

Notes:

  • monitor the response to titration of medicines closely in people who have heart failure with reduced ejection fraction and chronic kidney disease, taking into account the increased risk of hyperkalaemia.

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.